EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 溫州康寧醫院股份有限公司 | | 股份代號 | 02120 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年6月30日止六個月之中期股息 | | 公告日期 | 2025年8月12日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 中期（半年期） | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年6月30日 | | 宣派股息 | 每 10 股 1.8 RMB | | 股東批准日期 | 有待公佈 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 有待公佈 | | 匯率 | 有待公佈 | | 除淨日 | 20 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 截至2025年6月30日止六個月的半年度業績公告 1 1 引言 1.1 董事會欣然宣佈本集團於本報告期之未經審核半年度業績，以及連同截至 2024年6月30日止六個月的數字比較。 1.2 本集團於本報告期的財務報告（「財務報告」）乃按中國企業會計準則編製。 2 財務摘要 2.1 主要財務數據及指標 | | 截至6月30日止六個月 | | | --- | --- | --- | | | 2025年 | 2024年 | | | 人民幣千元 | 人民幣千元 | | | （未經審核） | （未經審核） | | 營業收入 | 738,562 | 828,957 | | 除所得稅前利潤 | 41,980 | 61,513 | | 所得稅費用 | 15,210 | 16,516 | | 淨利潤 | 26,769 | 44,996 | | 歸屬於本公司股東的淨利潤 | 36,530 | 50,724 | | 少數股東損 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02120 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 19,598,900 | RMB | | | 1 RMB | | 19,598,900 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 19,598,900 | RMB | | | 1 RMB | | 19,598,900 | | 2. 股份分類 | 普通股 | 股份類別 | | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | ...

格隆汇7月31日丨康宁医院(02120.HK)宣布，董事会会议将于2025年8月12日（星期二）举行，藉以（其 中包括）审议及批准（如适当）公司及其附属公司截至2025年6月30日止六个月的半年度业绩及其发 布，以及考虑派发中期股息。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通知的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本通知全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 承董事會命 董事長 董事會會議通知 溫州康寧醫院股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，董事會會 議將於2025年8月12日（星期二）舉行，藉以（其中包括）審議及批准（如適當）本 公司及其附屬公司截至2025年6月30日止六個月之半年度業績及其發佈，以及考 慮派發中期股息。 溫州康寧醫院股份有限公司 管偉立 中國•浙江 2025年7月31日 截至本通知日期，本公司執行董事為管偉立先生、王蓮月女士及王健先生；非執 行董事為秦浩先生及李昌浩先生；及獨立非執行董事為鐘文堂女士、金玲女士及 陳世強先生。 ...

Financial Performance - Total revenue for 2024 reached RMB 1,654,289,000, representing an increase of 3.6% compared to RMB 1,596,266,000 in 2023[7] - Net profit attributable to shareholders for 2024 was RMB 65,610,000, a decrease of 23.6% from RMB 85,948,000 in 2023[7] - The group's total revenue for the reporting period was RMB 1,654.3 million, an increase of 3.6% compared to 2023, with self-operated hospital revenue reaching RMB 1,517.8 million, up 2.2%[30] - Net profit attributable to shareholders was RMB 65.6 million, a decrease of 23.7% compared to 2023[30] - The gross profit margin for self-owned hospitals increased to 25.9% from 25.4% in 2023, with total gross profit rising to RMB 438.4 million, a 6.6% increase[40] - The total gross profit for the group reached RMB 438.4 million, a 6.6% increase from 2023, with a gross margin of 26.5%[59][61] - Cash generated from operating activities was RMB 99.6 million, a decrease of RMB 165.4 million compared to RMB 265.0 million in 2023, primarily due to an increase in accounts receivable from medical insurance by RMB 134.9 million[40] - The income tax expense for the reporting period was RMB 17.7 million, a 44.5% increase from RMB 12.3 million in 2023, with effective tax rates of 26.0% in 2024 and 12.4% in 2023[71] Assets and Liabilities - Total assets as of December 31, 2024, were RMB 3,004,953,000, a slight decrease from RMB 3,047,687,000 in 2023[7] - The total liabilities as of December 31, 2024, were RMB 1,661,651,000, compared to RMB 1,639,481,000 in 2023[7] - The asset-liability ratio increased to 55.3% as of December 31, 2024, compared to 53.8% as of December 31, 2023[101] - As of December 31, 2024, accounts receivable increased to RMB 571.8 million, a 36.0% increase from RMB 420.4 million in 2023, mainly due to changes in medical insurance pre-settlement rules[73] Operational Highlights - The company operated 25 specialized mental health hospitals, generating revenue of RMB 1,056,000,000 during the reporting period[10] - Revenue from elderly care services amounted to RMB 462,000,000, indicating a growing demand and improved profitability[10] - The group operates 32 self-owned hospitals as of December 31, 2024, with the number of operational beds increasing to 11,508 from 11,268 in 2023[30] - The elderly care segment generated approximately RMB 461.9 million in medical business revenue, accounting for 30.4% of the group's self-operated hospital revenue[33] - Self-owned hospital billings amounted to RMB 1,582.1 million, a 2.9% increase from 2023, driven by an increase in outpatient and inpatient visits[44] Market Trends and Government Policies - As of the end of 2024, the elderly population aged 60 and above in China is projected to exceed 310 million, accounting for 22% of the total population[19] - The demand for elderly medical services is expected to surge significantly, leading to continuous expansion of the elderly healthcare market in China[19] - The government has introduced a series of policies to encourage social capital investment in the elderly healthcare sector, providing strong policy support for its development[19] - The "14th Five-Year" public service plan emphasizes the expansion of psychiatric and geriatric medical personnel to meet growing healthcare demands[17] - The government encourages the establishment of integrated medical and elderly care institutions to address the health needs of the aging population[20] Strategic Initiatives - The company plans to strengthen its internet hospital platform and optimize the pharmaceutical supply chain to meet diverse health needs[10] - The company aims to develop a core competitive advantage in elderly care services, integrating it with mental health operations for future growth[10] - The company aims to enhance operational efficiency and leverage information technology to strengthen its market position in mental health services[29] - Future strategies include deepening the integration of medical and financial operations, optimizing asset management, and advancing digitalization and AI applications[37] - The company is accelerating its layout in the elderly medical service sector, aiming to construct a diversified business growth curve[29] Research and Development - The group reported a total of 25 research projects submitted and 164 academic papers published, including 85 SCI papers, showcasing strong research innovation capabilities[35] - Research and development expenses amounted to RMB 36.5 million, a 12.5% increase from 2023, representing 2.4% of the self-owned hospital operating revenue[65] Shareholder and Governance Matters - The company distributed dividends totaling RMB 32,700,000, accounting for approximately 49.8% of the net profit attributable to shareholders[11] - The board proposed a final cash dividend of RMB 3 per 10 shares, totaling RMB 21,801,000, which represents 33.2% of the net profit attributable to shareholders for the reporting period[143] - The company has implemented an equity incentive plan, with a total of 2,460,000 incentive shares granted, representing 3.39% of the total issued share capital[105] - The stock incentive plan aims to grant a maximum of 2,460,000 shares, representing 3.39% of the company's total issued shares (excluding treasury shares) and 4.66% of the total non-listed circulating domestic shares[108] - The company has adhered to corporate governance codes and best practices during the reporting period[184] Employee and Talent Management - The total number of full-time employees increased to 4,869 as of December 31, 2024, from 4,765 in the previous year, with total employee compensation amounting to RMB 644.1 million[102] - The company emphasizes the importance of medical talent training and development, implementing annual training plans for employees[131] Environmental and Social Responsibility - The company is committed to environmental responsibility and has engaged third parties for proper disposal of medical waste[137] - Charitable donations and other contributions totaled approximately RMB 2.7 million for the year ended December 31, 2024[156]

Financial Performance - For the fiscal year ending December 31, 2024, the company reported total revenue of RMB 1,654.3 million, representing a 3.6% increase compared to RMB 1,596.3 million in 2023[4]. - The net profit attributable to shareholders for the same period was RMB 65.6 million, a decrease of 23.7% from RMB 85.9 million in 2023[4]. - The total assets of the company as of December 31, 2024, were RMB 3,004.9 million, a slight decrease from RMB 3,047.7 million in 2023[4]. - The company reported a net cash outflow from operating activities of RMB 99.6 million, down from RMB 265.0 million in 2023[4]. - The group reported a billable income of RMB 1,582.1 million for owned hospitals, a growth of 2.9% compared to 2023, driven by an increase in outpatient and inpatient visits[18]. - Total operating revenue for 2024 reached RMB 1,654,289,413, an increase of 3.7% compared to RMB 1,596,265,532 in 2023[106]. - Total operating costs for 2024 were RMB 1,549,653,899, up from RMB 1,495,651,128 in 2023, reflecting a growth of 3.6%[106]. - Net profit for 2024 decreased to RMB 50,397,711, down 42% from RMB 86,931,608 in 2023[107]. - Basic and diluted earnings per share for 2024 were both RMB 0.88, compared to RMB 1.15 in 2023[108]. Operational Metrics - The company operated 32 hospitals as of December 31, 2024, maintaining the same number as in 2023, with total operational beds increasing to 11,508 from 11,268[6]. - Revenue from owned hospital operations was RMB 1,517.8 million, an increase of 2.2% from 2023[14]. - The gross profit margin for owned hospitals improved to 25.9%, up from 25.4% in 2023[14]. - The total revenue from inpatient services for the year ended December 31, 2024, was RMB 933.7 million, a 0.4% increase compared to 2023, driven by a 5.6% growth in inpatient bed days due to new acquisitions[22]. - Outpatient revenue for the same period reached RMB 173.5 million, reflecting a 4.9% increase, supported by a 20.1% rise in outpatient visits despite a 12.6% decrease in average spending per visit[22]. - The average occupancy rate for inpatient services improved to 88.4% in 2024 from 85.9% in 2023, with total inpatient bed days increasing to 2,889,163[21]. - The total revenue from pharmaceutical sales was RMB 218.1 million, up 4.6% from RMB 208.4 million in 2023[22]. Research and Development - The company submitted 25 research projects and published 164 academic papers, including 85 SCI papers, showcasing strong research innovation capabilities[10]. - Research and development expenses amounted to RMB 36.5 million, a 12.5% increase from 2023, representing 2.4% of self-owned hospital operating revenue[38]. - Research and development expenses increased to RMB 36,519,661 in 2024, up from RMB 32,466,196 in 2023, indicating a growth of 12.6%[106]. Elderly Care Services - The elderly care business generated approximately RMB 461.9 million in medical revenue, accounting for 30.4% of the company's self-operated hospital revenue[9]. - The company is actively expanding its elderly care services, with six elderly hospitals opened and one health care project under construction[9]. - The total revenue from elderly care inpatient services was RMB 439.7 million, marking a 12.9% increase, attributed to a 23.4% rise in inpatient bed days[26]. - The average expenditure for elderly care outpatient services decreased significantly, leading to a 33.5% drop in outpatient revenue for elderly care[26]. Financial Position and Liabilities - The balance of bank borrowings as of December 31, 2024, was RMB 946.2 million, an increase from RMB 864.7 million as of December 31, 2023, due to repayments of RMB 367.0 million and new borrowings of RMB 448.5 million[69]. - The asset-liability ratio increased to 55.3% as of December 31, 2024, compared to 53.8% as of December 31, 2023[75]. - The company's total liabilities decreased to RMB 1,994,721,479 in 2024 from RMB 2,060,039,035 in 2023[110]. - The total liabilities to equity ratio for 2024 is approximately 1.24, indicating a slight increase from the previous year's ratio[111]. Shareholder Returns and Dividends - The board of directors has proposed a final dividend of RMB 3 per 10 shares, totaling RMB 21.801 million, which represents 33.2% of the net profit attributable to the parent company's shareholders for the reporting period[82]. - The total proposed dividends for the 2024 interim and final periods amount to RMB 32.701 million, accounting for 49.8% of the net profit attributable to the parent company's shareholders[82]. - The proposed final dividend for the year ended December 31, 2024, is RMB 21,801,000, based on 72,670,000 shares, pending shareholder approval[135]. - The company plans to distribute an interim dividend of RMB 10,900,500 for the six months ended June 30, 2024, also based on 72,670,000 shares, subject to approval at the upcoming extraordinary general meeting[135]. Corporate Governance and Compliance - The audit committee reviewed the financial performance for the fiscal year ending December 31, 2024, and confirmed compliance with applicable accounting standards[89]. - The company has adhered to all corporate governance codes during the reporting period[90]. - The financial statements were prepared in accordance with the Enterprise Accounting Standards and based on the going concern principle[96]. - The company has not made any significant changes to its accounting policies that would materially affect its financial position[101]. Employee and Management - The company has a total of 4,869 full-time employees as of December 31, 2024, compared to 4,765 employees as of December 31, 2023, with employee compensation amounting to RMB 644.1 million, up from RMB 607.4 million in 2023[76]. - The average employee compensation, including social insurance and housing fund contributions, is RMB 132.3 thousand per year[76]. - The board of directors includes experienced executives, which may contribute to strategic decision-making and governance[142].

Revenue and Profit Performance - Total revenue for the first half of 2024 reached RMB 829.0 million, a 6.6% increase compared to the same period last year[19] - Revenue from self-operated hospitals amounted to RMB 765.6 million, a 5.1% year-on-year growth[19] - Net profit attributable to shareholders of the company was RMB 50.7 million, up 15.9% from the previous year[19] - The company's total revenue for the first half of 2024 reached RMB 829.0 million, a 6.6% increase compared to the same period in 2023[25] - Net profit attributable to shareholders increased by 15.9% year-over-year to RMB 50.7 million in the first half of 2024[25] - The company's self-operated hospitals achieved a gross profit margin of 27.5% in the first half of 2024, up from 24.9% in the same period in 2023[25] - The company's self-operated hospitals generated billable revenue of RMB 784.9 million, a 5.5% increase compared to the same period in 2023[27] - The company's self-operated hospitals achieved a gross profit of RMB 229.7 million, a 16.8% increase compared to the same period in 2023[28] - Total revenue for the first half of 2024 reached RMB 828.96 million, a 6.56% increase compared to RMB 777.93 million in the same period last year[116] - Net profit for the first half of 2024 was RMB 44.99 million, a decrease of 7.66% from RMB 48.73 million in the same period last year[118] - Operating profit for the first half of 2024 was RMB 63.83 million, a 12.97% increase compared to RMB 56.50 million in the same period last year[118] - Net profit for the period was RMB 29,384,349.62, compared to a net loss of RMB -8,676,844.29 in the previous period[120] - Comprehensive income attributable to the parent company was RMB 50,723,744.20, compared to RMB 43,750,057.46 in the previous period[119] Hospital Operations and Performance - The number of self-operated hospitals remained at 32, with the number of operational beds increasing to 11,648 from 11,268 at the end of 2023[19] - Some hospitals, such as Huainan Kangning Hospital and Changchun Kanglin Psychological Hospital, showed significant performance growth due to refined management measures[22] - Hospitals like Beijing Yining Hospital and Shenzhen Yining Hospital faced challenges due to high property costs, leading to cumulative losses[22] - Revenue from self-operated hospitals accounted for RMB 765.6 million, representing 31.1% of the company's total self-operated hospital revenue, with the elderly medical sector showing initial scale[24] - The company operates 6 elderly hospitals and has 1 health care project under construction, with a total of approximately 2,730 beds[24] - The elderly medical sector generated revenue of RMB 238.1 million in the first half of 2024, with some hospitals showing significant growth compared to the same period in 2023[24] - Hospital bill income increased by 6.2% to RMB 677.2 million, driven by a 15.2% growth in hospital bed days due to new acquisitions and expansions[32] - Outpatient bill income slightly increased by 1.2% to RMB 107.7 million, with outpatient visits decreasing by 3.0% but average outpatient spending per visit rising by 4.2%[32] - Treatment and general medical service income grew by 5.2%, accounting for 78.7% of the hospital's operating income, while drug sales income increased by 6.5%, making up 21.3%[32] - Outpatient visits totaled 243,108 in the first half of 2024, with outpatient revenue reaching RMB 107.7 million[29] Financial Position and Cash Flow - Operating cash flow for the first half of 2024 was RMB 116.5 million, compared to RMB 113.6 million in the same period last year[17] - Total assets as of June 30, 2024, were RMB 3,008.4 million, slightly down from RMB 3,047.7 million at the end of 2023[18] - Total liabilities decreased to RMB 1,581.9 million from RMB 1,639.5 million at the end of 2023[18] - Equity attributable to shareholders of the company increased to RMB 1,290.9 million from RMB 1,265.1 million at the end of 2023[18] - The company's own hospital revenue costs increased by 1.4% to RMB 555.2 million, with employee benefits and expenses rising by 9.3% and drug and consumable costs decreasing by 6.1%[33] - Gross profit for the company's own hospital business increased by 16.1% to RMB 210.4 million, with the gross margin rising to 27.5%, up 2.6 percentage points from the previous year[37] - Other medical-related business income reached RMB 63.0 million, with non-hospital drug and medical device sales contributing RMB 41.7 million[34] - Property rental income decreased significantly to RMB 0.3 million due to new lease conditions and the return of subleased properties[35] - Management expenses increased by 4.3% to RMB 106.3 million, primarily due to a 15.1% rise in employee benefits and expenses[41] - The company's comprehensive gross margin improved to 27.3%, up from 25.9% in the previous year[37] - Sales expenses increased to RMB 9.2 million, accounting for 1.2% of the company's own hospital operating income[39] - R&D expenses increased by 17.6% to RMB 17.6 million, accounting for 2.3% of the company's self-operated hospital revenue[43] - Net financial expenses rose to RMB 24.5 million, with interest expenses on borrowings increasing by RMB 4.0 million compared to the same period in 2023[45] - Investment income reached RMB 1.7 million, primarily due to a RMB 1.4 million gain from the disposal of equity in Hangzhou Yining Hospital[46] - Credit impairment losses increased to RMB 5.6 million, up from RMB 3.0 million in the same period last year[47] - Non-operating income decreased by RMB 5.4 million to RMB 0.5 million, mainly due to a RMB 5.5 million reduction in donations received[49] - Income tax expenses grew by 43.9% to RMB 16.5 million, with the effective tax rate rising to 26.9% from 19.1%[50] - Accounts receivable increased by 6.6% to RMB 448.1 million, with a turnover period of 95 days[54] - Construction in progress rose to RMB 234.0 million, primarily due to new projects at Lucheng Yining Hospital and Linhai Cining Hospital[56] - Net cash generated from operating activities amounted to RMB 116.5 million, including a net profit of RMB 45.0 million and adjustments for depreciation and amortization of RMB 79.4 million[62] - Net cash used in investing activities amounted to RMB 112.7 million, primarily due to the purchase of property, plant, and equipment totaling RMB 111.0 million, including infrastructure investments in hospitals such as Lucheng Yining Hospital and Quzhou Yining Hospital[63] - Net cash outflow from financing activities was RMB 41.7 million during the reporting period[66] - Bank loan balance as of June 30, 2024, was RMB 923.3 million, an increase from RMB 864.7 million as of December 31, 2023, driven by repayments of RMB 304.8 million and new borrowings of RMB 363.4 million[66] - The company's asset-liability ratio slightly decreased to 52.6% as of June 30, 2024, compared to 53.8% as of December 31, 2023[72] - The company had 4,742 employees as of June 30, 2024, with total employee compensation (including salaries and benefits) of approximately RMB 313.8 million, up from RMB 291.5 million in the same period last year[73] - The average employee salary (including social insurance and housing fund contributions) was RMB 132.4 thousand per year[73] - The company's lease liabilities, excluding amounts due within one year, stood at RMB 158.9 million as of June 30, 2024[69] - The company did not engage in any significant investments, acquisitions, or disposals during the six months ended June 30, 2024[66] - Total assets as of June 30, 2024, amounted to RMB 3,008,351,772.44, a slight decrease from RMB 3,047,686,606.84 at the end of the previous year[109] - Current assets totaled RMB 957,021,290.30, with cash and cash equivalents at RMB 373,302,433.47, down from RMB 418,861,721.39 at the end of the previous year[108] - Non-current assets amounted to RMB 2,051,330,482.14, including fixed assets of RMB 782,127,103.00 and intangible assets of RMB 307,875,476.38[109] - Long-term equity investments increased to RMB 141,550,815.01 from RMB 139,071,987.05 at the end of the previous year[109] - Accounts receivable increased to RMB 448,102,421.02 from RMB 420,441,069.56 at the end of the previous year[108] - Inventory decreased to RMB 51,889,640.76 from RMB 60,600,180.25 at the end of the previous year[108] - Construction in progress increased significantly to RMB 234,034,296.61 from RMB 186,980,240.67 at the end of the previous year[109] - Total liabilities decreased to RMB 1,581,889,916.28 from RMB 1,639,480,660.02 compared to the end of the previous year[111] - Total owner's equity increased to RMB 1,426,461,856.16 from RMB 1,408,205,946.82[111] - Short-term borrowings decreased to RMB 111,000,000.00 from RMB 127,001,700.00[110] - Accounts payable increased to RMB 112,544,938.03 from RMB 110,060,007.67[110] - Long-term borrowings increased to RMB 768,224,669.65 from RMB 557,719,214.69[110] - Total current assets increased to RMB 856,201,535.51 from RMB 847,091,576.19[112] - Long-term equity investments increased to RMB 793,380,629.16 from RMB 785,983,439.17[113] - Fixed assets decreased to RMB 283,949,624.57 from RMB 288,701,322.35[113] - Intangible assets decreased to RMB 23,105,075.42 from RMB 23,680,002.23[113] - Total assets increased to RMB 2,068,476,006.37 from RMB 2,050,057,345.62[113] - Total liabilities as of June 30, 2024, amounted to RMB 804.83 million, a slight increase from RMB 794.29 million at the end of the previous year[114] - Short-term borrowings decreased by 11.20% to RMB 111.00 million as of June 30, 2024, compared to RMB 125.00 million at the end of the previous year[114] - Long-term borrowings increased by 39.85% to RMB 506.30 million as of June 30, 2024, compared to RMB 362.04 million at the end of the previous year[114] - Total equity as of June 30, 2024, was RMB 1.26 billion, a slight increase from RMB 1.26 billion at the end of the previous year[115] - R&D expenses for the first half of 2024 were RMB 17.59 million, a 17.58% increase compared to RMB 14.96 million in the same period last year[116] - Financial expenses for the first half of 2024 were RMB 24.47 million, a 21.36% increase compared to RMB 20.16 million in the same period last year[116] - The company's total assets as of June 30, 2024, were RMB 2.07 billion, a slight increase from RMB 2.05 billion at the end of the previous year[115] - Operating revenue for the period was RMB 193,286,941.03, an increase from RMB 176,204,799.00 in the previous period[120] - Basic earnings per share (EPS) for the period was RMB 0.68, up from RMB 0.59 in the previous period[119] - Cash flow from operating activities was RMB 116,535,983.61, slightly higher than RMB 113,591,338.70 in the previous period[122] - Sales of goods and services generated RMB 774,736,897.94 in cash, down from RMB 780,086,767.35 in the previous period[122] - R&D expenses increased to RMB 12,778,787.81 from RMB 9,690,626.11 in the previous period[120] - Investment income for the period was RMB 14,189,338.60, compared to a loss of RMB -775,547.72 in the previous period[120] - Interest expenses for the period were RMB 13,692,407.18, up from RMB 11,787,407.21 in the previous period[120] - Investment activities generated a net cash outflow of RMB 112.71 million, compared to RMB 119.12 million in the previous period[123] - Financing activities resulted in a net cash outflow of RMB 41.66 million, a significant decrease from the net inflow of RMB 9.79 million in the previous period[123] - The company's cash and cash equivalents decreased by RMB 37.93 million, compared to an increase of RMB 4.27 million in the previous period[124] - Operating activities generated a net cash inflow of RMB 20.38 million, down from RMB 53.71 million in the previous period[124] - The company received RMB 362.77 million in borrowings, an increase from RMB 251.05 million in the previous period[123] - The company repaid RMB 304.77 million in debt, significantly higher than the RMB 109.63 million repaid in the previous period[123] - The company invested RMB 111.00 million in fixed assets, intangible assets, and other long-term assets, slightly higher than the RMB 107.84 million invested in the previous period[123] - The company's cash and cash equivalents balance at the end of the period was RMB 366.79 million, compared to RMB 262.87 million in the previous period[124] - The parent company's cash and cash equivalents decreased by RMB 19.60 million, compared to an increase of RMB 45.81 million in the previous period[125] - The parent company received RMB 293.00 million in borrowings, an increase from RMB 199.05 million in the previous period[125] - Total owner's equity as of June 30, 2024, was RMB 1,408,205,946.82, with minority interests amounting to RMB 143,141,250.58[126] - The company's capital reserve remained unchanged at RMB 38,399,577.13 for the period[126][129] - Net profit attributable to the parent company's owners decreased by RMB 11,942,120.95 compared to the previous period[126] - Owner's equity decreased by RMB 8,566,709.51 due to capital reduction and owner's investment[126][143] - The company's share capital remained stable at RMB 74,600,300.00[126][153] - Comprehensive income for the period showed a decrease of RMB 2,382,931.61 compared to the previous period[129] - The company's undistributed profit decreased by RMB 22,380,090.00 due to profit distribution[139] - Total owner's equity at the beginning of the year was RMB 1,265,064,696.24[126] - The company's special reserve decreased by RMB 3,375,411.44 during the period[126] - Owner's equity at the end of the period was RMB 1,263,645,164.63[140] - Total owner's equity as of June 30, 2024, is RMB 1,226,134,196.95[161] - Undistributed profits amount to RMB 241,903,691.18[161] - Surplus reserve stands at RMB 38,399,577.13[161] - The company's registered capital is RMB 74,600,300.00[162] - Cumulative issued share capital as of June 30, 2024, is 74.60 million shares[163] - The company's main business activities include operating psychiatric hospitals and providing hospital management services[163] - The company's actual controllers are Guan Weili and his spouse Wang Lianyue[163] - The company's income tax rate is 15%[166] - The company's subsidiary, Zhejiang Jieling Health Technology Co., Ltd., has a 15% income tax rate[167] - The company has applied for high-tech enterprise qualification and expects to receive the certificate by December 2024, which would reduce its income tax rate to 15%[167] - Total monetary funds decreased to RMB 373.3 million from RMB 418.9 million at the end of the previous year, with bank deposits accounting for the majority at RMB 367.2 million[169] - Trading financial assets increased slightly to RMB 7.6 million, all of which are equity instrument investments[170] - Accounts receivable increased to RMB 500.9 million, with 88.6% (RMB 443.6 million) within 1 year and bad debt provision increased to RMB 52.8 million[173] - Significant bad debt provision for patient medical fee arrears was RMB 24.3 million, representing 84.56% of the total amount[175] -

Financial Performance - Total revenue for the first half of 2024 reached RMB 829.0 million, a 6.6% increase compared to RMB 777.9 million in the same period of 2023[2] - Net profit attributable to shareholders for the first half of 2024 was RMB 50.7 million, reflecting a 15.9% increase from RMB 43.8 million in the previous year[3] - Operating income from self-owned hospitals amounted to RMB 765.6 million, up 5.1% year-on-year[3] - The overall gross profit increased to RMB 226.2 million, reflecting a growth of 12.2% compared to 2023[7] - The cash generated from operating activities was RMB 116.5 million, a 2.6% increase compared to the same period in 2023[7] - The company achieved revenue of RMB 829.0 million, a 6.6% increase compared to the same period in 2023[7] - The total revenue from treatment and general medical services was RMB 617.7 million, an increase of 5.2% year-on-year[11] - Total operating revenue for the six months ended June 30, 2024, was RMB 828,957,554, an increase from RMB 777,925,164 for the same period in 2023, reflecting a growth of approximately 6.5%[70] - Total profit for the first half of 2024 reached CNY 61,512,576, up from CNY 60,207,112 in 2023, indicating a growth of about 2.2%[73] Operational Highlights - The total number of self-owned hospitals remained at 32, with an increase in operational bed count to 11,648 from 11,268 as of December 31, 2023[3] - Revenue from elderly care services reached approximately RMB 238.1 million, accounting for 31.1% of the operating income from self-owned hospitals[6] - The group opened 6 elderly hospitals and has 1 ongoing health care project, with around 2,730 beds available[6] - The company's self-operated hospital billing revenue was RMB 784.9 million, a 5.5% increase year-on-year, driven by increased outpatient and inpatient visits[9] - The average bed occupancy rate for inpatient services improved to 87.4%, up from 84.0% in the previous year[10] - The company expanded its hospital bed capacity to 11,648 beds, an increase from 10,578 beds in the previous year[10] Financial Position - Total assets as of June 30, 2024, were RMB 3,008.4 million, a slight decrease from RMB 3,047.7 million at the end of 2023[2] - Total liabilities decreased to RMB 1,581.9 million from RMB 1,639.5 million at the end of 2023[2] - As of June 30, 2024, inventory balance was RMB 519 million, down from RMB 606 million as of December 31, 2023[28] - Accounts receivable balance increased to RMB 4,481 million, a growth of 6.6% from RMB 4,204 million as of December 31, 2023, mainly due to increased operating income from self-owned hospitals[29] - The group’s debt-to-asset ratio slightly decreased to 52.6% from 53.8% as of December 31, 2023[48] - The company reported cash and cash equivalents of CNY 373,302,433 as of June 30, 2024, down from CNY 418,861,721 at the end of 2023, a decrease of about 10.9%[76] Expenses and Costs - The group's self-owned hospital operating costs increased to RMB 555.2 million, a slight increase of 1.4% compared to RMB 547.5 million in the same period of 2023[13] - Employee benefits and expenses accounted for 41.1% of self-owned hospital operating costs, up from 38.1% in the same period of 2023[14] - Management expenses totaled RMB 106.3 million, a 4.3% increase from RMB 101.9 million in the same period of 2023, with employee benefits and expenses rising by 15.1%[20] - Research and development expenses rose to RMB 17.6 million, a 17.6% increase from RMB 15.0 million in the same period of 2023, representing 2.3% of self-owned hospital operating revenue[21] - Financial expenses net amount was RMB 24.5 million, an increase of RMB 4.3 million compared to the same period in 2023, primarily due to an increase in borrowing interest expenses[23] Shareholder Information - The company proposed a mid-term dividend of RMB 1.50 per 10 shares, totaling approximately RMB 11,077,260, which represents 21.8% of the net profit attributable to shareholders for the reporting period[65] - Basic and diluted earnings per share for the first half of 2024 were both CNY 0.68, compared to CNY 0.59 in the same period of 2023, marking an increase of about 15.3%[75] - The proposed cash dividend for the interim profit distribution is RMB 1.50 per 10 shares, amounting to a total of RMB 11,077,260 based on the current share capital[94] Strategic Initiatives - The group aims to enhance operational management and adapt to new policies in the healthcare sector, focusing on mental health and elderly care as core business areas[6] - The group is actively adjusting operational strategies in response to underperforming hospitals due to local healthcare insurance settlement discrepancies[4] - The company plans to expand its market presence and invest in new product development, although specific figures were not disclosed[86] - The company’s strategy includes potential mergers and acquisitions to enhance growth opportunities in the future[86] Compliance and Governance - The audit committee has reviewed the interim performance announcement and confirmed compliance with applicable accounting standards and regulations[64] - The company has complied with all corporate governance codes during the reporting period[67] - The financial statements are prepared in accordance with the Chinese Accounting Standards and are consistent with the accounting policies used for the 2023 annual financial statements[69] Employee Information - The group employed 4,742 employees as of June 30, 2024, a decrease from 4,765 employees as of December 31, 2023[49] - Employee compensation for the reporting period was approximately RMB 313.8 million, compared to RMB 291.5 million for the six months ended June 30, 2023[49] - The average employee compensation, including social insurance and housing fund contributions, was RMB 132.4 thousand per year[49]

Financial Performance - Total revenue for 2023 reached RMB 1,596.3 million, a 7.5% increase compared to 2022[4] - Revenue from self-operated hospitals in 2023 was RMB 1,485.2 million, an 8.7% increase from 2022[4] - Net profit attributable to shareholders in 2023 was RMB 85.9 million, turning a profit compared to 2022[4] - The company's ROE (Return on Equity) for 2023 was 7.0%[4] - Revenue for 2023 reached RMB 1,596,266 thousand, a 7.5% increase from RMB 1,484,903 thousand in 2022[27] - Net profit attributable to the company's shareholders in 2023 was RMB 85,948 thousand, a significant improvement from a loss of RMB 24,221 thousand in 2022[27] - Total assets increased to RMB 3,047,687 thousand in 2023, up 15.5% from RMB 2,637,787 thousand in 2022[27] - Total liabilities rose to RMB 1,639,481 thousand in 2023, a 24.9% increase from RMB 1,311,885 thousand in 2022[27] - The company's equity attributable to shareholders grew to RMB 1,265,065 thousand in 2023, up 5.3% from RMB 1,201,585 thousand in 2022[27] - Total revenue for 2023 reached RMB 1,596.3 million, a 7.5% increase compared to 2022[63] - Revenue from self-operated hospitals grew to RMB 1,485.2 million, an 8.7% increase year-over-year[63] - Net profit attributable to shareholders was RMB 85.9 million, turning around from a loss in 2022, with a return on equity of 7.0%[63] - The company achieved revenue of RMB 1,596.3 million in 2023, a 7.5% increase compared to 2022, with self-operated hospital revenue reaching RMB 1,485.2 million, an 8.7% increase[71] - Gross profit margin for self-operated hospitals improved to 25.4% in 2023, up from 23.9% in 2022, with overall gross profit increasing by 16.5% to RMB 411.1 million[71] - Net profit attributable to shareholders was RMB 85.9 million in 2023, turning around from a loss in 2022[71] - Operating cash flow increased by 16.6% to RMB 265.0 million in 2023 compared to RMB 227.2 million in 2022[71] - Self-operated hospital billable revenue reached RMB 1,537.4 million in 2023, a 7.9% increase, driven by growth in outpatient and inpatient visits[73] - Variable consideration decreased to RMB 52.2 million in 2023, accounting for 3.4% of billable revenue, down from 4.1% in 2022[73] - Public medical insurance settlements accounted for 68.7% of the company's cash received from sales and services in 2023, maintaining a similar proportion to previous years (68.6% in 2021 and 69.3% in 2022)[69] - The company's self-operated hospital billable revenue increased to RMB 1,537,406 thousand in 2023 from RMB 1,425,005 thousand in 2022[94] - The company's outpatient billable revenue reached RMB 218.3 million in 2023, a 5.6% increase compared to 2022, despite a 5.0% decrease in outpatient visits[101] - The average outpatient expenditure per visit increased by 11.2% to RMB 436 in 2023[99] - The company's gross profit from self-operated hospitals increased to RMB 429,486 thousand in 2023 from RMB 384,890 thousand in 2022[96] - The company's treatment and general medical service revenue reached RMB 1,214,672 thousand in 2023, up from RMB 1,119,887 thousand in 2022[99] - The company's drug sales revenue increased to RMB 322,734 thousand in 2023 from RMB 305,118 thousand in 2022[99] - The company's own hospital revenue costs increased to RMB 1,107.9 million, a 6.5% growth compared to 2022, driven by a 7.7% increase in drug and consumable expenses, an 11.6% rise in employee benefits and expenses due to increased hospital beds, and a 9.1% decrease in asset depreciation and amortization[105] - The gross margin for the company's own hospital business increased to 25.4% in 2023 from 23.9% in 2022, while the overall gross margin rose to 25.8% from 23.8%[106] - The company's own hospital billable income increased by RMB 112.4 million compared to 2022, with a gross profit growth of 11.6% due to increased inpatient bed days and cost control[119] - The number of inpatient beds at the end of the period was 11,268, up from 9,688 in 2022, with an effective inpatient service bed day capacity of 4,112,820, compared to 3,536,120 in 2022[120] - Inpatient billable income reached RMB 1,319.1 million, an 8.3% increase from 2022, driven by a 10.7% growth in inpatient bed days[121] - The company's total gross profit reached RMB 411.1 million, a 16.5% increase from 2022, with the gross profit of the own hospital business reaching RMB 377.2 million, a 15.5% growth[125] - The company's comprehensive gross margin increased to 25.8% in 2023 from 23.8% in 2022, with the gross margin of the own hospital business growing by 1.5 percentage points[126] - Management expenses were RMB 213.0 million, a 3.5% increase from 2022, with employee benefits and expenses rising by 5.5%[129] - R&D expenses were RMB 32.5 million, a 1.7% decrease from 2022, accounting for 2.2% of the company's own hospital operating income[131] - The company's net financial expenses were RMB 41.5 million, a decrease of RMB 2.9 million from 2022, with a 9.1% reduction in loan interest expenses due to lower bank loan interest rates[111] - Credit impairment losses decreased to RMB 9.4 million in 2023 from RMB 25.2 million in 2022[133] - Investment losses amounted to RMB 6.1 million, including a one-time impairment of RMB 6.8 million due to the acquisition of Chengdu Yining Hospital[154] - Accounts receivable increased by 9.8% to RMB 420.4 million as of December 31, 2023, driven by increased revenue from the company's self-operated hospitals[137] - Construction in progress increased to RMB 187.0 million, primarily due to new construction projects at Lucheng Yining Hospital and Linhai Cining Hospital[139] - Net cash generated from operating activities was RMB 265.0 million, including net profit of RMB 85.9 million and adjustments for depreciation and amortization of RMB 159.4 million[142] - Net cash used in investing activities was RMB 215.0 million, mainly due to the purchase of property, plant, and equipment totaling RMB 179.7 million[143] - Income tax expense decreased by 53.9% to RMB 12.3 million, with the effective tax rate dropping to 12.4% from 170.3% in 2022[135] - Sales expenses increased to RMB 17.1 million, accounting for 1.2% of the company's self-operated hospital revenue[149] - Other receivables and prepayments increased to RMB 79.5 million as of December 31, 2023, up from RMB 69.4 million in 2022[138] - Inventory balance increased to RMB 60.6 million, primarily consisting of pharmaceutical stock and consumables[159] - Right-of-use assets decreased to RMB 189.1 million as of December 31, 2023 (RMB 190.4 million as of December 31, 2022), mainly due to depreciation[162] - Bank loan balance increased to RMB 864.7 million as of December 31, 2023 (RMB 616.5 million as of December 31, 2022), with repayments of RMB 357.7 million and new borrowings of RMB 605.9 million during the reporting period[167] - Lease liabilities totaled RMB 163.2 million as of December 31, 2023, excluding RMB 28.6 million due within one year[169] - The company had 4,765 full-time employees as of December 31, 2023 (4,196 as of December 31, 2022), with total employee compensation of RMB 607.4 million (RMB 529.4 million in 2022) and average annual compensation of RMB 127.5 thousand[170] - The net cash generated from financing activities for the reporting period was RMB 96.1 million[187] - The total mortgage loan balance as of December 31, 2023, was RMB 260.0 million for Wenzhou Kangning Hospital, RMB 75.1 million for Wenzhou Lucheng Yining Hospital, RMB 25.0 million for Jinyuan Shuning Hospital, and RMB 37.7 million for Quzhou Yining Hospital[188] - The asset-liability ratio increased slightly to 53.8% as of December 31, 2023, compared to 49.7% as of December 31, 2022, primarily due to an increase in bank borrowings[190] Hospital Operations and Expansion - The number of self-operated hospitals increased from 29 at the end of 2022 to 32 at the end of 2023[4] - Operational beds increased from 9,688 at the end of 2022 to 11,268 at the end of 2023[4] - The company acquired controlling stakes in Loudi Kangning Hospital, Dongkou Lening Hospital, and Chengdu Yining Hospital in 2023[4] - The number of self-operated hospitals increased to 32, including one independent internet hospital (Yining Psychological Internet Hospital)[63] - Operational beds expanded to 11,268, up from 9,688 at the end of 2022[63] - The company acquired 51% equity in Loudi Kangning Hospital and Dongkou Lenning Hospital, and completed the acquisition of Chengdu Yining Hospital to expand its mental health specialty network[66] - The company's regional management model showed increasing agglomeration effects, with self-operated hospitals in Taizhou and Haixi regions achieving stable year-on-year growth[64] - The company operates 6 elderly hospitals with approximately 2,540 beds as of December 31, 2023[88] - The company is actively promoting hospital rating evaluations to improve service quality and competitiveness, with its flagship hospital successfully passing the third-level A-grade psychiatric hospital review[89] - The company's own hospital billable income increased by RMB 112.4 million compared to 2022, with a gross profit growth of 11.6% due to increased inpatient bed days and cost control[119] - The number of inpatient beds at the end of the period was 11,268, up from 9,688 in 2022, with an effective inpatient service bed day capacity of 4,112,820, compared to 3,536,120 in 2022[120] - Inpatient billable income reached RMB 1,319.1 million, an 8.3% increase from 2022, driven by a 10.7% growth in inpatient bed days[121] Strategic Focus and National Policies - The company is upgrading its internet hospital platform and strengthening its pharmaceutical supply chain[4] - The company is focusing on the development of mental health and elderly medical services, aligning with national health strategies[3][8] - The Chinese government has set a goal to build a social environment conducive to the mental health of children and adolescents by 2022, with a focus on prevention and intervention measures for mental health issues and disorders[12] - By 2025, China plans to construct 100 mental health welfare facilities in regions with insufficient mental health service capabilities, targeting vulnerable populations such as children and individuals with mental disorders[13] - The "14th Five-Year Plan" for public services emphasizes expanding the scale of psychiatrists and registered nurses, improving mental health diagnosis and treatment capabilities, and encouraging social forces to participate in the supply of medical services[14] - By 2050, China's elderly population aged 60 and above is projected to exceed 500 million, accounting for 38.81% of the total population, signaling a significant market opportunity in elderly healthcare[15] - The Chinese government has issued policies encouraging private capital to participate in the elderly care industry, promoting the integration of medical and elderly care services[15] - The State Council has advocated for the development of smart elderly care services, leveraging internet resources and social forces to provide home-based care services such as health management and rehabilitation[16] - The Zhejiang Provincial Health Commission supports the development of specialized hospitals, particularly in areas like rehabilitation, nursing, and elderly care, encouraging chain and brand development[14] - The Chinese government has introduced policies to support the establishment of medical and elderly care integration institutions, addressing the growing demand for elderly health services[16] - The company emphasized the importance of expanding elderly care, rehabilitation, and maternal care services in line with national policies[42][55][57][59][60][61] - The company is focusing on the growing demand for mental health and elderly medical services, leveraging the window of opportunity created by the "Healthy China" strategy[70] - The company's elderly medical business achieved revenue of approximately RMB 427.1 million in 2023, accounting for 28.8% of the group's self-operated hospital revenue[88] Equity Incentive and Shareholder Information - The company plans to distribute at least 30% of annual net profit as cash dividends from 2023 to 2027, with the goal of increasing this ratio to 50%[7] - No shares were awarded, canceled, or expired under the H-share incentive trust plan during the reporting period[30] - The total number of incentive shares granted under the H-share incentive trust plan and other share plans must not exceed 1% of the company's issued share capital[31] - No shareholders waived or agreed to waive any dividends as of December 31, 2023[34] - The company's main business location is in Wenzhou, Zhejiang Province, China[23] - The company's H-share trading price was approximately HKD 40.00 per share (approximately RMB 32.50 per share) as of May 29, 2018[29] - The company granted a total of 2,454,632 incentive shares to employees, with 133,715 shares granted to senior management and 1,684,814 shares to core technical personnel[43] - No securities were issued during the reporting period[49] - No management contracts were signed for the entire business or main business during the reporting period[51] - The company did not have any approved indemnity provisions as of December 31, 2023[47] - The equity incentive plan granted a total of 2,460,000 shares, representing 3.30% of the company's total share capital and 4.45% of non-tradable domestic shares[179] - The equity incentive plan had 193 grantees, with 1,818,529 shares granted in the first phase, 180,516 shares in the second phase, and 540,229 shares in the third phase[173] - The equity incentive plan has a 48-month lock-up period from the grant date, with a grant price of RMB 10.47 per share[173] - The company had no significant investments, acquisitions, or disposals during the reporting period[166] - The equity incentive plan allows grantees to indirectly hold company shares through a limited partnership employee持股平台[177] - The equity incentive plan grants grantees rights such as dividends and voting rights, which are not restricted by the lock-up period[177] - The company implemented an H-share incentive trust plan to retain core technical and management personnel, approved at the 2023 first extraordinary general meeting on September 27, 2023[186] - The company revised the 2018 equity incentive plan in 2021, removing performance assessment requirements and the obligation to repurchase unvested incentive shares[191] - The equity incentive plan aims to align the interests of shareholders, the company, and the core team, ensuring long-term development and strategic goals[193] - The scope of incentive targets includes directors, supervisors, senior management, core technical (business) personnel, and other personnel deemed necessary by the board of directors[194] - The specific list of incentive targets and their subscription amounts will be determined by the board of directors[195] - The equity incentive plan involves the form of equity, the source and type of shares, and the quantity and proportion of shares relative to the company's total share capital[196] - The equity incentive plan has a validity period of 10 years from April 26, 2018, with approximately 4 years remaining as of the report date[198] - The lock-up period for incentive shares is 48 months from the date of grant[199] - The first batch of incentive shares was fully unlocked on June 28, 2022, 48 months after the initial grant date (June 29, 2018)[200] Risks and Challenges - The company faces risks of professional medical talent shortages, which could impact its ability to provide ideal medical services[90]